Identification of genes responsible for the resistance to first line anti-myeloma therapeutics

Research Project

Project/Area Number	24K11532
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 54010:Hematology and medical oncology-related
Research Institution	The University of Tokyo
Principal Investigator	リズクモハメド・カーメル・アブデルバシール・ヘラル・オラ東京大学, 医科学研究所, 特任研究員 (60823698)
Project Period (FY)	2024-04-01 – 2027-03-31
Project Status	Granted (Fiscal Year 2024)
Budget Amount *help	¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000) Fiscal Year 2026: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2025: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2024: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords	myeloma
Outline of Research at the Start	Multiple myeloma (MM) is an incurable plasma cell malignancy. In this study, I will use CRISPR-Cas9 knockout screening to identify genes involved in the resistance to the first line chemotherapeutic agents in MM using human and murine MM cell lines. I will perform CRISPR-Cas9 KO screening in the presence of inhibitors and validate the potential target genes involved in drug resistance and dissect their roles in the pathogenesis of MM.